Jazz Pharmaceuticals plc
For the period ended Sep 30, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 2, 2026
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY(Registrant)
/s/ Renee D. Gala
Renee D. Gala
President and Chief Executive Officer and Director(Principal Executive Officer)
/s/ Philip L. Johnson
Philip L. Johnson
Executive Vice President and Chief Financial Officer(Principal Financial Officer)
/s/ Patricia Carr
Patricia Carr
Senior Vice President, Chief Accounting Officer(Principal Accounting Officer)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.